| Overview |
| bs-20164R-APC-Cy5 |
| CBY1 Polyclonal Antibody, APC-Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| APC-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CBY1 |
| 51-126/126 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 25776 |
| Q9Y3M2 |
| Nucleus |
| CBY; arb1; PGEA1; C22orf2; PIGEA14; PIGEA-14; HS508I15A; Protein chibby homolog 1; ARPP-binding protein; Cytosolic leucine-rich protein; PKD2 interactor, Golgi and endoplasmic reticulum-associated 1; CBY1; HRIHFB2025 |
| Inhibits the Wnt/Wingless pathway by binding to CTNNB1/beta-catenin and inhibiting beta-catenin-mediated transcriptional activation through competition with TCF/LEF transcription factors. Has also been shown to play a role in regulating the intracellular trafficking of polycystin-2/PKD2 and possibly of other intracellular proteins. Promotes adipocyte and cardiomyocyte differentiation. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz